Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 14 DECEMBER 2022

ESG Weekly Update – December 7, 2022

Debevoise & Plimpton
Explore more from Debevoise & Plimpton

On December 6, 2022, Republican members of Congress sent a letter to executives of the Steering Committee for Climate Action 100+, noting the role the organization plays in efforts...

GlobalCorporate/Commercial Law
Geoffrey P. Burgess
Geoffrey P. Burgess
Andrew M. Levine
Andrew M. Levine
Sue Meng
Sue Meng
William D. Regner
William D. Regner
David W. Rivkin
David W. Rivkin
Jeffrey J. Rosen
Jeffrey J. Rosen
Samantha J. Rowe
Samantha J. Rowe
Caroline N. Swett
Caroline N. Swett
Patricia Volhard
Patricia Volhard
+15 more

U.S.: House Republicans Launch Investigation into "Climate Cartel"

On December 6, 2022, Republican members of Congress sent a letter to executives of the Steering Committee for Climate Action 100+, noting the role the organization plays in efforts to advance firms' ESG policies. Climate Action 100+ is an investor-led initiative that aims to ensure that the world's largest corporate greenhouse gas emitters act on climate change.

The letter requests information about ESG-related conduct or agreements that, the authors of the letter state, could be unlawful under U.S. antitrust laws. The letter requests numerous documents by December 20, 2022.

The letter also includes a formal request to preserve all existing and future records and materials relating to facilitating and coordinating companies' efforts to achieve ESG-related goals.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP